Grassley briefs Dems on outstanding FDA issues

Share this article:
Outgoing Senate Finance Committee chairman Chuck Grassley (R-IA) has written Democrat Senate HELP Committee leaders with a laundry list of FDA shortcomings that he hopes they will address in the new session beginning in January. In a letter, he summarized “systemic” FDA problems, such as drug safety, scientific morale, and a “too cozy” relationship with the industries it regulates.

Grassley complained about FDA senior officials who “disregarded and downplayed important concerns and warnings from its own scientists,” and their pressures to have scientists change their findings or conclusions regarding a safety or efficacy issue.

The day after Grassley sent his letter, incoming HELP Committee chairman Edward M. Kennedy (D-MA) took the opportunity of the committee's last, lame-duck session to lambaste their impact on the FDA.

“Science has, too often, had to take a backseat at the very agency which should be setting the standard for objectivity and integrity,” he said.  

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.